Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-Tamrada
- Development stage
- Preclinical
- Lead developer
- Ironfist Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
177Lu-Tamrada is a first-in-class **nanomedicine radiopharmaceutical** that selectively targets **tumor associated macrophages (TAMs)** without a targeting ligand, delivering the radioactive isotope lutetium-177 (177Lu) directly to TAMs within the tumor microenvironment. It is designed to treat a range of solid tumors, including anti-PD-1 resistant triple negative breast cancer, by arresting tumor growth and exerting cytotoxic effects via radiation and a bystander effect, killing adjacent tumor cells. Its mechanism unlocks the immune system and provides potential for broad application across tumor types with TAM involvement. The drug is under development by Ironfist Therapeutics[1].
- Brand names
- Tamrada
- Other names
- 177Lu-Tamrada
02
Targets
TAM (TAM receptor tyrosine kinases)
Beyond the preview
Go deeper on 177Lu-Tamrada.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-Tamrada.